Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cefscot is a combination antibiotic medication consisting of cefuroxime axetil and potassium clavulanate. Cefuroxime axetil is a second-generation cephalosporin that exerts its bactericidal effect by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins (PBPs). Potassium clavulanate is a beta-lactamase inhibitor that prevents the degradation of cefuroxime by beta-lactamase-producing bacteria, thereby extending its spectrum of activity. This combination is typically used for the treatment of respiratory tract infections, urinary tract infections, and skin and soft tissue infections caused by susceptible organisms. It is marketed as a branded generic by Pharma Drugs & Chemicals, often under a PCD (Propaganda Cum Distribution) franchise model.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cefuroxime axetil + clavulanic acid.